MedPath

Evaluation of Lotrafilcon A Lenses Over a Three Month Period

Not Applicable
Completed
Conditions
Myopia
Interventions
Device: Lotrafilcon A contact lens
Registration Number
NCT00931307
Lead Sponsor
CIBA VISION
Brief Summary

The purpose of this trial is to assess the performance of a Lotrafilcon A contact lens over a 3-month period.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
22
Inclusion Criteria
  • On examination, have ocular findings considered to be "normal" and which would not prevent a subject from safely wearing contact lenses.
  • Be willing and able to follow instructions and meet the schedule of follow-up visits as defined in the informed consent.
  • Be able to wear the study lenses in the available powers.
  • Currently wear contact lenses for a minimum of 5 days a week, and at least 8 hours a day.
  • Other protocol inclusion/exclusion criteria may apply.
Exclusion Criteria
  • Eye injury or surgery within twelve weeks immediately prior to enrollment for this trial.
  • Pre-existing ocular irritation that would preclude contact lens fitting.
  • Currently enrolled in an ophthalmic clinical trial.
  • Evidence of systemic or ocular abnormality, infection or disease likely to affect successful wear of contact lenses or use of their accessory solutions.
  • Any use of medications for which contact lens wear would be contraindicated, in the opinion of the investigator.
  • History of corneal refractive surgery.
  • Other protocol inclusion/exclusion criteria may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Lotrafilcon ALotrafilcon A contact lens-
Primary Outcome Measures
NameTimeMethod
Comfort After Insertion3 months

Comfort after insertion of contact lens (30 seconds to 1 minute), as interpreted by the subject and reported by the subject as a single, retrospective evaluation of 3-month's wear time. Comfort after insertion was measured on a 10-point scale, with 1 being poor and 10 being excellent.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath